Galectin-1 mediated suppression of Epstein-Barr virus–specific T-cell immunity in classic Hodgkin lymphoma
Maher K. Gandhi(Translational Research Institute), Rajiv Khanna(QIMR Berghofer Medical Research Institute), Ujjwal Dua(The University of Melbourne), Olivier Ramuz(The University of Queensland), Guido Moll(Humboldt-Universität zu Berlin), Paula Marlton(The University of Queensland), Eleanore Lambley(The University of Melbourne), Corey Smith(QIMR Berghofer Medical Research Institute), John F. Seymour(The Royal Melbourne Hospital), Devinder Gill(Princess Alexandra Hospital)
Cited by 164
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL
|Blood|2018|1.7k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k